Bristol Myers (BMY) Gets a Hold Rating from Credit Suisse

Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (BMY) yesterday and set a price target of $59. The company’s shares closed on Friday at $49.89.

According to, Divan ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.6% and a 40.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.

Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $56.50, which is a 13.2% upside from current levels. In a report issued on January 25, Merrill Lynch also maintained a Hold rating on the stock with a $53 price target.

See today’s analyst top recommended stocks >>

Based on Bristol Myers’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.97 billion and net profit of $1.19 billion. In comparison, last year the company earned revenue of $5.45 billion and had a GAAP net loss of $2.33 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts